PURPOSE OF THE STUDY. The goal of this study was to determine if long-term treatment with oral immunotherapy (OIT) will result in sustained unresponsiveness to peanut.
STUDY POPULATION. The study enrolled 39 children, ages 1 to 16 years, with peanut allergy defined as a clinical history of a reaction to peanut within 60 minutes of ingestion, a positive peanut skin prick test (SPT) result $3 mm, and peanut-specific immunoglobulin (Ig)E $15 kU/L or with a positive SPT result and peanut IgE $7 kU/L and a clinical reaction within the previous 6 months. Subjects with poorly controlled or severe asthma and those with a history of severe anaphylaxis were excluded.
METHODS. Daily OIT was administered by using a standard protocol with initial dose escalation, build-up every 2 weeks to 4000 mg, and daily maintenance dosing for up to 5 years of therapy. Blinded oral food challenges (OFC) to 5000 mg of peanut were performed during and at the end of the study, including after 4 weeks of OIT cessation to assess sustained unresponsiveness. Peanut SPT, IgE testing, and immunologic assays were conducted throughout the study. A telephone survey was conducted at the end of the study to assess peanut consumption and symptoms noted.
RESULTS. Twenty-four of the 39 subjects completed the protocol. Six subjects withdrew due to allergic adverse effects, and 9 withdrew for other reasons. Twelve subjects demonstrated sustained unresponsiveness after the final OFC and were deemed treatment successes (TS) and were instructed to add peanut ad libitum to their diet; those not passing the final OFC were considered treatment failures (TF) and were instructed to continue dietary avoidance of peanuts. At baseline and final OFC, TS had smaller SPT results (P , .01) and lower peanut-specific IgE (P , .01), Ara h 1 (P , .05), and Ara h 2 (P , .01) levels plus a reduced peanut-specific IgE/total IgE ratio (P , .001) compared with TF. Peanut IgG4 levels did not differ between the 2 groups. Survey results showed that none of the TS reported allergic reactions to peanut compared with 14% of TF. TS consumed a median of 555 mg/d (0-4000 mg/d) of peanut 3 days per week (0-7 days/week).
CONCLUSIONS. This study is the first to show sustained unresponsiveness after peanut OIT noted in ∼50% of subjects treated for up to 5 years, results that persisted after OIT. Smaller SPT results and lower peanut-specific IgE levels strongly correlated with success of treatment.
REVIEWER COMMENTS. Sustained unresponsiveness in peanut OIT is a vital step in the treatment of peanut food allergies. This advancement in OIT is associated with direct benefit that likely requires ongoing antigen exposure for persistence. Further study in larger populations is needed to advance OIT as a viable treatment option for widespread use. PURPOSE OF THE STUDY. The goal of this study was to establish the efficacy of oral immunotherapy (OIT) for the desensitization of children with peanut allergy.
STUDY POPULATION. Children ages 7 to 16 years with an immediate peanut hypersensitivity reaction and a positive result on skin prick test and double-blind, placebo-controlled food challenge (DBPCFC) to peanut were recruited from allergy clinics and national patient support groups.
METHODS. In phase 1 of this unmasked, randomized, placebocontrolled trial, children in the active OIT group received 2 to 800 mg/d of peanut protein, and those in the control group continued to avoid peanut. The primary outcome was desensitization, defined as passing a DBPCFC to 1400 mg of peanut protein after 6 months. During phase 2, control participants remaining allergic to peanut received OIT and had a repeat DBPCFC. PURPOSE OF THE STUDY. The goal of this study was to assess the safety and efficacy of milk oral immunotherapy (OIT) in milk-allergic children and adults, including high-risk patients.
STUDY POPULATION. The study included 280 Israeli patients, ages 4 to 27 years (median age: 7.5 years), with persistent cow's milk allergy as defined by positive results on skin prick test and/or specific-serum IgE, positive oral food challenge, or history of clinical reaction with accidental exposure in the last 12 months. High-risk patients, including those with a history of anaphylaxis (as defined by involvement of at least 2 organ systems), were not excluded. In fact, 73% had a history of anaphylactic reaction. Patients with uncontrolled asthma were excluded.
METHODS.
Using an open-label individualized treatment program, monthly rounds of OIT were administered by using fresh cow's milk via a modified challenge-desensitization protocol. All patients were skin tested, with complete blood count and eosinophil counts obtained at the start of the program. The induction phase determined the maximal tolerated starting dose. This phase was performed in the hospital setting, with escalating doses of cow's milk and observation for reactions with appropriate treatment. By the second day, 98% of patients had exhibited reactions. The third and fourth days were used to repeat the maximum tolerated starting dose and verify that it was safe. During the home dosing phase, the maximum tolerated starting dose was then given twice daily at home for 24 days.
RESULTS. Five patients failed milk OIT during induction, and 15 patients were still being studied. Sixty-two percent of the remaining patients (160 of 260) were able to freely consume milk (.7200 mg), and 25% were able to tolerate smaller amounts, with 85% consuming at least 180 mg of cow's milk protein or the equivalent of 6 mL of milk. Clinically significant factors (P , .001) for achieving full tolerance to cow's milk protein included a higher starting dose (odds ratio: 4.6 [for .30 mg]), not requiring epinephrine during induction (odds ratio: 5.2), and lack of nonanaphylactic reactions (odds ratio: 15.6).
CONCLUSIONS. This study presents clinical factors that may be helpful in predicting which patients undergoing milk OIT might be able to achieve full consumption of cow's milk protein.
REVIEWER COMMENTS. Challenges exist to prescribing food OIT at this point due to several unresolved issues, and the approach is not currently approved. These challenges include optimal criteria for patient selection, timing and duration of treatment, and the optimal protocol to maximize safety and effectiveness. This study may help with patient selection and risk stratification. Even when subjects were unable to be successfully desensitized, they tolerated a "minimal protective dose." This approach would offer some protection against accidental ingestions and would greatly increase the quality of life for a number of patients. 
